Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF) was the target of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 114,947 shares, a decline of 20.8% from the February 26th total of 145,224 shares. Based on an average trading volume of 15 shares, the short-interest ratio is presently 7,663.1 days. Currently, 0.2% of the company’s shares are short sold.

Genmab A/S Price Performance

Shares of GNMSF stock opened at $267.20 on Tuesday. The company has a market capitalization of $16.45 billion, a P/E ratio of 17.26 and a beta of 0.92. The company’s 50-day simple moving average is $298.38 and its two-hundred day simple moving average is $306.60. Genmab A/S has a one year low of $170.00 and a one year high of $352.00. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01.

Genmab A/S (OTCMKTS:GNMSF) last released its quarterly earnings data on Tuesday, February 17th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $3.10 by ($2.55). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.